TM
(donislecel)
Lantidra™
First FDA-Approved, Cellular Therapy
to Treat Type 1 Diabetes
Lantidra™ (donislecel) is a breakthrough treatment approved for adults with type 1 diabetes (T1D) who experience severe hypoglycemia despite intensive diabetes management and education. Lantidra is the first FDA-approved allogeneic cellular therapy made from donor pancreatic islet cells for the treatment of T1D.
Why Lantidra ?
Proven Safety and Efficacy
The safety and effectiveness of Lantidra in subjects with type 1 diabetes and hypoglycemic unawareness was demonstrated in two clinical trials involving a combined 30 subjects, all of whom received at least one islet infusion and a maximum of three infusions. Both trials were prospective, open-label, single-arm studies. The most common side effects or adverse reactions are related to the need for immunosuppressive medications to maintain islet cell viability.
​
High Quality Pancreatic Islets
Quality control (QC) assessments are performed to confirm potency (functionality) and sterility of isolated islets. QC testing is performed in compliance with rigorous FDA standards. Release criteria are verified before approval of each Lantidra lot for transplantation. CellTrans, Inc. is the manufacturer of Lantidra.
​
Partnership with
University of Illinois Hospital (UIH)
Our current main healthcare institution partnership is with the University of Illinois Hospital (UIH) located in Chicago, IL. UIH is comprised of highly-skilled transplant surgeons and physicians to ensure the best clinical outcomes after administration of Lantidra.
​
​
​
​
​
Insurance Coverage Options
Lantidra is an FDA approved cell therapy to treat type 1 diabetes. FDA approved treatments may qualify for medical insurance coverage and reimbursement.
​
About Lantidra
At CellTrans, we are dedicated to providing innovative treatment options for adults with type 1 diabetes. Our unique approach is designed to help patients who experience severe hypoglycemia despite intensive diabetes management.
